Publication: The 'cephalosporin era' of triazole therapy: Isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections
Issued Date
2015-01-01
Resource Type
ISSN
17447666
14656566
14656566
Other identifier(s)
2-s2.0-84933544048
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Opinion on Pharmacotherapy. Vol.16, No.10 (2015), 1543-1558
Suggested Citation
Maria N. Chitasombat, Dimitrios P. Kontoyiannis The 'cephalosporin era' of triazole therapy: Isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Expert Opinion on Pharmacotherapy. Vol.16, No.10 (2015), 1543-1558. doi:10.1517/14656566.2015.1057500 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/36859
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The 'cephalosporin era' of triazole therapy: Isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections
Other Contributor(s)
Abstract
© 2015 Informa UK, Ltd. Introduction: Invasive fungal infections remain frequent life-threatening complications in immunocompromised patients. Each of the currently available antifungals has limitations in terms of pharmacokinetic and pharmacodynamic profile, spectrum of efficacy, and tolerability. Isavuconazole (ISA) is a new generation, broad-spectrum triazole that has a favorable spectrum of efficacy and is available in both intravenous and oral forms. Recent Phase III clinical studies showed that ISA had comparable efficacy to voriconazole for the treatment of a variety of mould infections.Areas covered: This review summarizes the literature on the use of ISA. PubMed was searched for publications in English from 2006 to December 2014 using the terms 'ISA', 'BAL4815', and 'BAL 8557'. Relevant publications were reviewed and reference lists were examined for further publications. Conference abstracts from the meeting during 2013-2014 were also reviewed.Expert opinion: ISA is a new broad spectrum triazole antifungal for the treatment of invasive fungal disease available as oral and intravenous formulations, and the ability to be administered as a once-daily regimen. ISA has broad-spectrum in vitro activity, favorable pharmacokinetic profile, and good tolerability. ISA may be considered for primary treatment for a vast variety of invasive fungal infections. Further study of ISA given as prophylaxis, combination, or salvage therapy is warranted.